Combined expertise: the anticancer alliance covers a wide spectrum of cancer medicine, ranging from fundamental research by the DKFZ to clinical application of, for example, the contrast agent Primovist® from Bayer HealthCare.
Successful therapeutic concepts to treat diseases that are as complex as cancer require comprehensive medical knowledge. After all, few other diseases present scientists and doctors with such huge challenges. Bayer HealthCare’s Bayer HealthCare Pharmaceuticals Division has therefore set up a strategic allicance with the German Cancer Research Center (DKFZ).
More effective treatment faster
The scientists want to combine the findings of basic research in oncology with experiences from pharmaceutical research & development more quickly and effectively. For Germany as a research location, this kind of collaboration between fundamental scientific research and industrial research is unprecedented. Find out more about the anticancer collaboration in which each partner will invest EUR 1.75 million through 2010 here.